NASDAQ:CVLB - Conversion Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.50
  • Forecasted Upside: 398.01 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.53
▼ -0.72 (-8.73%)
Get New Conversion Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVLB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVLB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$37.50
▲ +398.01% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Conversion Labs in the last 3 months. The average price target is $37.50, with a high forecast of $40.00 and a low forecast of $35.00. The average price target represents a 398.01% upside from the last price of $7.53.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Conversion Labs.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$15.00 ➝ $40.00Low
i
2/5/2021B. RileyInitiated CoverageBuy$35.00Low
i
Rating by A. D'silva at B. Riley
1/6/2021BTIG ResearchInitiated CoverageBuy$15.00N/A
i
(Data available from 4/22/2016 forward)
Conversion Labs logo
Conversion Labs, Inc. operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparation supplies for disaster situations, such as flu epidemics, bacterial outbreaks, bioterrorism and water supply failures, and others; and PDFSimpli, a PDF conversion software enables users to convert, edit, and sign PDF documents. It markets and sells its products through advertisements on Facebook, Google, Amazon, and other social media and e-commerce platforms. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was founded in 1994 and is based in New York, New York.
Read More

Today's Range

Now: $7.53
$7.53
$8.25

50 Day Range

MA: $23.15
$14.48
$30.55

52 Week Range

Now: $7.53
$0.50
$33.02

Volume

1,386,633 shs

Average Volume

1,046,458 shs

Market Capitalization

$174.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Conversion Labs?

The following sell-side analysts have issued research reports on Conversion Labs in the last twelve months: B. Riley, and BTIG Research.
View the latest analyst ratings for CVLB.

What is the current price target for Conversion Labs?

2 Wall Street analysts have set twelve-month price targets for Conversion Labs in the last year. Their average twelve-month price target is $37.50, suggesting a possible upside of 398.0%. BTIG Research has the highest price target set, predicting CVLB will reach $40.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $35.00 for Conversion Labs in the next year.
View the latest price targets for CVLB.

What is the current consensus analyst rating for Conversion Labs?

Conversion Labs currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CVLB will outperform the market and that investors should add to their positions of Conversion Labs.
View the latest ratings for CVLB.

What other companies compete with Conversion Labs?

How do I contact Conversion Labs' investor relations team?

Conversion Labs' physical mailing address is 800 THIRD AVENUE SUITE 2800, NEW YORK NY, 10022. The company's listed phone number is (866) 351-5907 and its investor relations email address is [email protected] The official website for Conversion Labs is www.conversionlabs.com.